1. Home
  2. BGX vs UNCY Comparison

BGX vs UNCY Comparison

Compare BGX & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Long Short Credit Income Fund

BGX

Blackstone Long Short Credit Income Fund

HOLD

Current Price

$10.81

Market Cap

135.2M

Sector

Finance

ML Signal

HOLD

Logo Unicycive Therapeutics Inc.

UNCY

Unicycive Therapeutics Inc.

HOLD

Current Price

$7.89

Market Cap

145.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGX
UNCY
Founded
N/A
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.2M
145.3M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
BGX
UNCY
Price
$10.81
$7.89
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$25.67
AVG Volume (30 Days)
48.2K
1.1M
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$675,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$582.86
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.38
$3.72
52 Week High
$12.65
$8.74

Technical Indicators

Market Signals
Indicator
BGX
UNCY
Relative Strength Index (RSI) 41.17 56.53
Support Level $10.76 $6.77
Resistance Level $10.97 $8.40
Average True Range (ATR) 0.06 0.63
MACD 0.00 0.08
Stochastic Oscillator 29.41 70.11

Price Performance

Historical Comparison
BGX
UNCY

About BGX Blackstone Long Short Credit Income Fund

Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The company's seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Share on Social Networks: